poisar

Stocks · News reference

'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolDavid Jagielski, Cpa

    Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

    Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.

  2. The Motley FoolJeff Siegel

    Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

    Canopy Growth is approaching positive adjusted EBITDA with Q1 fiscal 2027 revenue up 13% year-over-year to $57.4 million, narrowing adjusted EBITDA losses to $2.3 million from $5.7 million. The MTL Cannabis acquisition is driving growth across Canadian medical, adult-use, and international markets, with expected $7.2 million in annual cost savings. However, free cash flow deteriorated to a $18.5 million outflow, raising concerns about cash generation despite an encouraging balance sheet with $241.4 million in cash.

  3. SEC EDGARSEC EDGAR

    8-K filing — Cronos Group Inc. (CRON)

    Filed: 2026-09-11 AccNo: 0001656472-26-000058 Size: 171 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits